<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35171365</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1434-9949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical rheumatology</Title>
          <ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Altered levels of circulating CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T follicular cytotoxic cells in primary Sjögren's syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>1697</StartPage>
          <EndPage>1708</EndPage>
          <MedlinePgn>1697-1708</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-022-06098-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Circulating CD8<sup>+</sup> T-cells expressing the C-X-C chemokine receptor type 5 (CXCR5) (CD8<sup>+</sup>CXCR5<sup>+</sup>T), a recently identified follicular cytotoxic T cell subset, are involved in antiviral immunity and autoimmunity, but their abundance and role in the pathogenesis of primary Sjögren syndrome (pSS) are unknown.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Circulating CD8<sup>+</sup>CXCR5<sup>+</sup>T cell and CD8<sup>+</sup> regulatory T cells (CD8<sup>+</sup>Treg) were evaluated in 49 pSS patients (19 patients with pulmonary involvement) and 24 age- and sex-matched healthy controls (HCs) by flow cytometry. Orthogonal partial least squares discriminant analysis (OPLS-DA) was performed, and receiver operating characteristic curves (ROC) were generated to identify characteristic cell subsets. Spearman's correlation analysis was conducted to examine the relationships between CD8<sup>+</sup> T cell subsets and clinical features.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The proportions and numbers of CD8<sup>+</sup>CXCR5<sup>+</sup>, CD8 + CXCR5<sup>+</sup> programmed death 1-positive (PD-1<sup>+</sup>), and CD8<sup>+</sup>CXCR5<sup>-</sup>PD-1<sup>+</sup>T cells were significantly higher, whereas those of CD8<sup>+</sup>Treg were markedly lower, in pSS patients than HCs. The CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T cell to CD8<sup>+</sup>Treg ratio had the greatest discriminatory power for pSS and HCs according to OPLS-DA and ROC analyses. The increased numbers of CD8<sup>+</sup>CXCR5<sup>+</sup>T cells and CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T cells were strongly associated with those of CD4<sup>+</sup>CXCR5<sup>+</sup>T and B cells. The proportions and numbers of CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T cells were increased in pSS patients with lung involvement.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified a new CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T subset, which was increased in abundance in pSS patients, particularly those with lung involvement, compared with HCs. Also, the CD8<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>T to CD8<sup>+</sup>Treg ratio may be useful for identifying pSS. Our findings suggest that targeting follicular CD8<sup>+</sup>T cell subsets has therapeutic potential for pSS. Key Points • CD8+CXCR5+ T cells were expanded in the circulation of patients with pSS. • Reduced numbers CD8+Treg cells in pSS patients. • Increased CD8+CXCR5+PD-1+T cells in pSS patients with pulmonary involvement.</AbstractText>
          <CopyrightInformation>© 2022. International League of Associations for Rheumatology (ILAR).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhai</LastName>
            <ForeName>Xuwen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The Clinical Skills Teaching, Simulation Hospital of Shanxi Medical University, Jinzhong, 030600, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Yanlin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Guo</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, 518005, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Zhaojun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yanyao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xiangcong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Chong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-1242-0286</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China. ljty966@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Clin Rheumatol</MedlineTA>
        <NlmUniqueID>8211469</NlmUniqueID>
        <ISSNLinking>0770-3198</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095085">CXCR5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054380">Receptors, CXCR5</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054380" MajorTopicYN="N">Receptors, CXCR5</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD8+ regulatory T cells</Keyword>
        <Keyword MajorTopicYN="N">CD8+CXCR5+ follicular cytotoxic T subsets</Keyword>
        <Keyword MajorTopicYN="N">Lung involvement</Keyword>
        <Keyword MajorTopicYN="N">OPLS-DA</Keyword>
        <Keyword MajorTopicYN="N">Primary Sjögren’s syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35171365</ArticleId>
        <ArticleId IdType="doi">10.1007/s10067-022-06098-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s10067-022-06098-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fox RI (2005) Sjogren’s syndrome. Lancet 366:321–331. https://doi.org/10.1016/S0140-6736(05)66990-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)66990-5</ArticleId>
            <ArticleId IdType="pubmed">16039337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Astorri E, Scrivo R, Bombardieri M, Picarelli G, Pecorella I, Porzia A et al (2014) CX3CL1 and CX3CR1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in Sjogren’s syndrome. Rheumatology (Oxford) 53:611–620. https://doi.org/10.1093/rheumatology/ket401</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/ket401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fonseca VR, Romão VC, Agua DA, Santos M, Presa DL, Ferreira AC et al (2018) The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sjogren’s syndrome. Arthritis Rheumatol 70:774–784. https://doi.org/10.1002/art.40424</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.40424</ArticleId>
            <ArticleId IdType="pubmed">29361207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno H (2016) T follicular helper cells in human autoimmunity. Curr Opin Immunol 43:24–31. https://doi.org/10.1016/j.coi.2016.08.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2016.08.003</ArticleId>
            <ArticleId IdType="pubmed">27588918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Federico PC, Natalia AT, Maria TR (2018) Circulating CXCR5-expressing CD8+ T-cells are major producers of IL-21 and associate with limited HIV replication. J Acquir Immune Defic Syndr 78:473–482. https://doi.org/10.1097/QAI.0000000000001700</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/QAI.0000000000001700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai M, Zheng Y, Liu H, Su BW, Zhan Y, He H (2017) CXCR5+ CD8+ T cells potently infiltrate pancreatic tumors and present high functionality. Exp Cell Res 361:39–45. https://doi.org/10.1016/j.yexcr.2017.09.039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2017.09.039</ArticleId>
            <ArticleId IdType="pubmed">28965867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC et al (2016) Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417–421. https://doi.org/10.1038/nature19330</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature19330</ArticleId>
            <ArticleId IdType="pubmed">27501248</ArticleId>
            <ArticleId IdType="pmc">5297183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang YM, Zhang XY, Wagner UG, Yang HY, Beckenbaugh RD, Kurtin PJ et al (2002) CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 195:1325–1336. https://doi.org/10.1084/jem.20011565</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20011565</ArticleId>
            <ArticleId IdType="pubmed">12021312</ArticleId>
            <ArticleId IdType="pmc">2193749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shan Q, Zeng ZH, Xing SJ, Li FY, Hartwig SM, Gullicksrud JA et al (2017) The transcription factor Runx3 guards cytotoxic CD8(+) effector T cells against deviation towards follicular helper T cell lineage. Nat Immunol 18:931–939. https://doi.org/10.1038/ni.3773</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3773</ArticleId>
            <ArticleId IdType="pubmed">28604718</ArticleId>
            <ArticleId IdType="pmc">5564218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yu M, Zheng Y, Fu GP, Xin G, Zhu W et al (2019) CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance. Nat Commun 10:4415. https://doi.org/10.1038/s41467-019-12446-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12446-5</ArticleId>
            <ArticleId IdType="pubmed">31562329</ArticleId>
            <ArticleId IdType="pmc">6765049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le KS, Patricia AT, Tarte K, Rey FG, Granjeaud S, Orlanducci F et al (2018) CXCR5 and ICOS expression identifies a CD8 T-cell subset with T features in Hodgkin lymphomas. Blood Adv 2:1889–1900. https://doi.org/10.1182/bloodadvances</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances</ArticleId>
            <ArticleId IdType="pubmed">30087107</ArticleId>
            <ArticleId IdType="pmc">6093730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 33:775–787. https://doi.org/10.1016/j.cell.2008.05.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.05.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang XL, Smith TR, Kumar V (2005) Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2:11–19</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16212906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic selftolerance and negative control of immune responses. Annu Rev Immunol 22:531–562. https://doi.org/10.1146/annurev.immunol.21.120601.141122</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141122</ArticleId>
            <ArticleId IdType="pubmed">15032588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinesh RK, Skaggs BJ, La CA, Hahn BH, Singh RP (2010) CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 9:560–568. https://doi.org/10.1016/j.autrev.2010.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2010.03.006</ArticleId>
            <ArticleId IdType="pubmed">20385256</ArticleId>
            <ArticleId IdType="pmc">2879466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha S, Itani FR, Karandikar NJ (2014) Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res 59:254–265. https://doi.org/10.1007/s12026-014-8529-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12026-014-8529-9</ArticleId>
            <ArticleId IdType="pubmed">24845461</ArticleId>
            <ArticleId IdType="pmc">4125494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E (2008) CD8+CD28-, suppressive T cells in systemic lupus erythematosus. Lupus 17:630–637. https://doi.org/10.1177/0961203308089400</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203308089400</ArticleId>
            <ArticleId IdType="pubmed">18625635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L (2005) Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 174:5814–5822. https://doi.org/10.4049/jimmunol.174.9.5814</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.9.5814</ArticleId>
            <ArticleId IdType="pubmed">15843585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correale J, Villa A (2010) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 67:625–638. https://doi.org/10.1002/ana.21944</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21944</ArticleId>
            <ArticleId IdType="pubmed">20437560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HJ, Verbinne B, Tang X, Lu L, Cantor H (2010) Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 467:328–332. https://doi.org/10.1038/nature09370</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09370</ArticleId>
            <ArticleId IdType="pubmed">20844537</ArticleId>
            <ArticleId IdType="pmc">3395240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. https://doi.org/10.1136/ard.61.6.554</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.61.6.554</ArticleId>
            <ArticleId IdType="pubmed">12006334</ArticleId>
            <ArticleId IdType="pmc">1754137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E et al (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69:1103–1109. https://doi.org/10.1136/ard.2009.110619</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2009.110619</ArticleId>
            <ArticleId IdType="pubmed">19561361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol 21:656–660. https://doi.org/10.1136/jcp.21.5.656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.21.5.656</ArticleId>
            <ArticleId IdType="pubmed">5697370</ArticleId>
            <ArticleId IdType="pmc">473887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R et al (2017) Treatment guidelines for rheumatologic manifestations of Sjögren’s Syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 69:517–527. https://doi.org/10.1002/acr.22968</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.22968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB et al (2010) Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? Rheumatol Int 30:1317–1324. https://doi.org/10.1007/s00296-009-1152-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-009-1152-8</ArticleId>
            <ArticleId IdType="pubmed">19844720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li BC, Guo QL, Wang YY, Su R, Gao C, Zhao JF et al (2020) Increased serum interleukin-2 levels are associated with abnormal peripheral blood natural killer cell levels in patients with active rheumatoid arthriti. Mediators Inflamm 2020:6108342. https://doi.org/10.1155/2020/6108342</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/6108342</ArticleId>
            <ArticleId IdType="pubmed">33013198</ArticleId>
            <ArticleId IdType="pmc">7512106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM (2018) Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol 112:94–101</Citation>
        </Reference>
        <Reference>
          <Citation>Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S (2016) Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev 25:110–123. https://doi.org/10.1183/16000617.0011-2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/16000617.0011-2016</ArticleId>
            <ArticleId IdType="pubmed">27246587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leong YA, Chen YP, Ong HS, Wu D, Man K, Deleage C et al (2016) CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol 17:1187–1196. https://doi.org/10.1038/ni.3543</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3543</ArticleId>
            <ArticleId IdType="pubmed">27487330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrando-Martinez S, Moysi E, Pegu A, Andrews S, Makamdop KN, Ambrozak D et al (2018) Accumulation of follicular CD8+ T cells in pathogenic SIV infection. J Clin Inves 128:2089–2103. https://doi.org/10.1172/JCI96207</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI96207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nurieva RI, Podd A, Chen YH, Alekseev AM, Yu M, Qi XP et al (2012) STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem 287:11234–11239. https://doi.org/10.1074/jbc.M111.324046</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.324046</ArticleId>
            <ArticleId IdType="pubmed">22318729</ArticleId>
            <ArticleId IdType="pmc">3322890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Guo LQ, Sun HW, Xu JB, Ba T (2018) CXCR5+ CD8 T cells displayed higher activation potential despite high PD-1 expression, in tumor-involved lymph nodes from patients with thyroid cancer. Int Immunopharmacol 62:114–119. https://doi.org/10.1016/j.intimp.2018.07.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.07.002</ArticleId>
            <ArticleId IdType="pubmed">30005226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C (2008) A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29:127–137. https://doi.org/10.1016/j.immuni.2008.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2008.06.001</ArticleId>
            <ArticleId IdType="pubmed">18602282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malik A, Sharma D, Zhu QF, Karki R, Guy CS, Vogel P et al (2016) IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis. J Clin Invest 126:4469–4481. https://doi.org/10.1172/JCI88625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI88625</ArticleId>
            <ArticleId IdType="pubmed">27775548</ArticleId>
            <ArticleId IdType="pmc">5127671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J, Yu Y, Ma JL, Ren CY, Chen WQ (2019) PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology (Oxford) 58:2188–2192. https://doi.org/10.1093/rheumatology/kez228</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M et al (2015) Human and mouse CD8(+)CD25(+)FOXP3(+) regulatory T cells at steady state and during interleukin-2 therapy. Front Immunol 6:171. https://doi.org/10.3389/fimmu.2015.00171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2015.00171</ArticleId>
            <ArticleId IdType="pubmed">25926835</ArticleId>
            <ArticleId IdType="pmc">4397865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao M, Hao ZY, Guo YY, Zhang XY, Zhang SX, Luo J et al (2018) Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome. Ann Rheum Dis 77:1838–1840. https://doi.org/10.1136/annrheumdis-2018-213036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-213036</ArticleId>
            <ArticleId IdType="pubmed">29936436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eusebio M, Kraszula L, Kupczyk M, Kuna P, Pietruczuk M (2012) Low frequency of CD8+CD25+FOXP3(BRIGHT) T cells and FOXP3 mRNA expression in the peripheral blood of allergic asthma patients. J Biol Regul Homeost Agents 26:211–220</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22824748</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
